Who Buys Raltegravir from India — 39 Importers Behind a $6.4M Market
India's raltegravir import market is served by 39 active buyers who collectively imported $6.4M across 113 shipments. TO EVEREST BANK LIMITED, (NEPAL) leads with a 9.8% market share, followed by N.P.C.SAC. and MAH DAROUYE HAKIM. The top 5 buyers together control 23.1% of total import value, reflecting a moderately competitive buyer landscape.
Raltegravir buyer data — 39 importers · $6.4M market · 113 shipmentsTransData Nexus · Indian Customs Data
Top Raltegravir Importers — Ranked by Import Value
TO EVEREST BANK LIMITED, (NEPAL) is the leading raltegravir importer from India, holding a 9.8% share of the $6.4M market across 113 shipments from 39 buyers. The top 5 buyers — TO EVEREST BANK LIMITED, (NEPAL), N.P.C.SAC. (PERU), MAH DAROUYE HAKIM (IRAN), DIRECTORATE OF CENTERS FOR INFECTIOUS DISEASES HOSPITAL C CHOGANLY (TURKMENISTAN), EMIRATES POST COMPANY (UNITED ARAB EMIRATES) — collectively control 23.1% of total import value.
Top Raltegravir Buyers & Importers
Ranked by import value · 39 active buyers · Indian Customs (DGFT) data
Mar 2026
Top Raltegravir Buyers & Importers — Ranked by Import Value. 39 active buyers with import value, shipments, country and supplier data compiled from Indian Customs records by TransData Nexus.
Which companies are buying Raltegravir — and from which countries?
Flow of Raltegravir exports from India: each country's share and the named importers behind the numbers
Raltegravir — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Top 5 importing countries account for 88.5% of global Raltegravir imports — led by Guatemala (32.6%) with a total trade value of $6.4M across 113 shipments from India.
Market Analysis: Top Importing Countries & Their Importers
1Guatemala
Guatemala emerges as the first largest importing country, achieving a total trade value of $2.1M through 0 shipments. This represents a market share of 32.6% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: Guatemala demonstrates strong market positioning with an average shipment value of $2.1M, indicating premium pricing strategy compared to the market average of $57.0K.
Guatemala is a key market for Raltegravir imports, representing 32.6% of total trade value.
Primary Market
Secondary Market
2Peru
Peru emerges as the second largest importing country, achieving a total trade value of $1.9M through 2 shipments. This represents a market share of 30.1% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Peru has a diverse importer base, with their top importers including:
• N.P.C.SAC. - $429.0K (22.2% of country's total business)
The buyers of Raltegravir imported from India can be categorized into the following segments:
1. Government Procurement Agencies: Entities responsible for national healthcare procurement, often purchasing through tenders to supply public health institutions.
*TO EVEREST BANK LIMITED* (Nepal): Likely acting on behalf of the Nepalese government for public health procurement.
*DIRECTORATE OF CENTERS FOR INFECTIOUS DISEASES HOSPITAL C CHOGANLY* (Turkmenistan): A government body managing infectious disease hospitals.
*DIRECTOR OF SPENCS AND SUPPLIES* (Oman): Oversees procurement and supply for public health facilities.
These agencies typically engage in bulk purchasing through formal tender processes, ensuring consistent supply for national healthcare programs. Their order patterns are periodic, aligning with budget cycles and public health needs.
2. Distributors: Companies that import pharmaceuticals to distribute within their domestic markets, supplying hospitals, clinics, and pharmacies.
*N.P.C.SAC.* (Peru): A distributor supplying Raltegravir to various healthcare providers.
1. Drug Regulatory Authority: Ministry of Public Health and Social Assistance (MSPAS), specifically the Division of Registration and Control of Medicines and Foods (DRCPFA).
2. Import Registration Process for Raltegravir:
Obtain a sanitary registration from DRCPFA.
Submit completed application forms in original and duplicate.
Provide product composition and formula (common and scientific names).
Include a valid foreign sanitary license (e.g., FDA or PAHO).
Legalized trademark registration.
Free Sale Certificate from the country of origin, certified by WHO or equivalent authority.
Monograph (if applicable for new products).
3. Estimated Timeline for Registration: Approximately 4-6 months.
The demand for Raltegravir in importing countries is primarily driven by the prevalence of HIV/AIDS, as Raltegravir is an integrase inhibitor used in antiretroviral therapy. According to the World Health Organization (WHO), as of 2024, approximately 38 million people worldwide were living with HIV, with significant populations in regions such as sub-Saharan Africa, Asia, and Latin America. Countries like Guatemala, Peru, and Nepal have reported increasing HIV incidence rates, necessitating the importation of effective antiretroviral medications like Raltegravir.
Government healthcare programs and the expansion of universal health coverage have also contributed to the demand. Many countries have included antiretroviral drugs in their national essential medicines lists, aligning with WHO's Essential Medicines List, which recommends Raltegravir for HIV treatment. Procurement through international organizations such as the Global Fund and UNICEF, as well as national tenders, facilitates the availability of Raltegravir in these markets. The presence of 39 buyers across 27 countries, as per TransData Nexus data, indicates a broad and sustained demand for Raltegravir, presenting ongoing market opportunities for exporters.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Common Questions — Raltegravir Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest raltegravir buyer importing from India?
Based on import volume and value, TO EVEREST BANK LIMITED, (NEPAL) leads with $632.2K in imports and a 9.8% market share — the highest of any single raltegravir importer. N.P.C.SAC. (PERU) and MAH DAROUYE HAKIM (IRAN) are the next largest buyers.
QHow many companies buy raltegravir from India?
There are 39 active raltegravir buyers importing from India, with a combined market of $6.4M across 113 shipments to 27 countries. The top 5 buyers hold 23.1% of total import value, while the remaining 34 buyers handle the other 76.9%.
QWhich countries import the most raltegravir from India?
The top importing countries for raltegravir from India are Guatemala (32.6%), Peru (30.1%), Panama (12.0%), Nepal (9.8%), Libya (4.0%). These markets represent the largest demand centres for Indian pharmaceutical exports of raltegravir, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for raltegravir from India?
The average import transaction value for raltegravir from India is $57.0K, with an average unit price of . Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
The buyers of Raltegravir imported from India can be categorized into the following segments:
1. Government Procurement Agencies: Entities responsible for national healthcare procurement, often purchasing through tenders to supply public health institutions.
*TO EVEREST BANK LIMITED* (Nepal): Likely acting on behalf of the Nepalese government for public health procurement.
*DIRECTORATE OF CENTERS FOR INFECTIOUS DISEASES HOSPITAL C CHOGANLY* (Turkmenistan): A government body managing infectious disease hospitals.
*DIRECTOR OF SPENCS AND SUPPLIES* (Oman): Oversees procurement and supply for public health facilities.
These agencies typically engage in bulk purchasing through formal tender processes, ensuring consistent supply for national healthcare programs. Their order patterns are periodic, aligning with budget cycles and public health needs.
2. Distributors: Companies that import pharmaceuticals to distribute within their domestic markets, supplying hospitals, clinics, and pharmacies.
*N.P.C.SAC.* (Peru): A distributor supplying Raltegravir to various healthcare providers.
1. Drug Regulatory Authority: Ministry of Public Health and Social Assistance (MSPAS), specifically the Division of Registration and Control of Medicines and Foods (DRCPFA).
2. Import Registration Process for Raltegravir:
Obtain a sanitary registration from DRCPFA.
Submit completed application forms in original and duplicate.
Provide product composition and formula (common and scientific names).
Include a valid foreign sanitary license (e.g., FDA or PAHO).
Legalized trademark registration.
Free Sale Certificate from the country of origin, certified by WHO or equivalent authority.
Monograph (if applicable for new products).
3. Estimated Timeline for Registration: Approximately 4-6 months.
The demand for Raltegravir in importing countries is primarily driven by the prevalence of HIV/AIDS, as Raltegravir is an integrase inhibitor used in antiretroviral therapy. According to the World Health Organization (WHO), as of 2024, approximately 38 million people worldwide were living with HIV, with significant populations in regions such as sub-Saharan Africa, Asia, and Latin America. Countries like Guatemala, Peru, and Nepal have reported increasing HIV incidence rates, necessitating the importation of effective antiretroviral medications like Raltegravir.
Government healthcare programs and the expansion of universal health coverage have also contributed to the demand. Many countries have included antiretroviral drugs in their national essential medicines lists, aligning with WHO's Essential Medicines List, which recommends Raltegravir for HIV treatment. Procurement through international organizations such as the Global Fund and UNICEF, as well as national tenders, facilitates the availability of Raltegravir in these markets. The presence of 39 buyers across 27 countries, as per TransData Nexus data, indicates a broad and sustained demand for Raltegravir, presenting ongoing market opportunities for exporters.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Key Insight: Peru demonstrates strong market positioning with an average shipment value of $967.2K, indicating premium pricing strategy compared to the market average of $57.0K.
Peru is a key market for Raltegravir imports, representing 30.1% of total trade value.
Primary Market
Secondary Market
3Panama
Panama emerges as the third largest importing country, achieving a total trade value of $775.1K through 0 shipments. This represents a market share of 12.0% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: Panama demonstrates strong market positioning with an average shipment value of $775.1K, indicating premium pricing strategy compared to the market average of $57.0K.
Panama is a key market for Raltegravir imports, representing 12.0% of total trade value.
Primary Market
Secondary Market
4Nepal
Nepal emerges as the fourth largest importing country, achieving a total trade value of $632.2K through 3 shipments. This represents a market share of 9.8% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Nepal has a diverse importer base, with their top importers including:
• TO EVEREST BANK LIMITED, - $632.2K (100.0% of country's total business)
Key Insight: Nepal demonstrates strong market positioning with an average shipment value of $210.7K, indicating premium pricing strategy compared to the market average of $57.0K.
Nepal is a key market for Raltegravir imports, representing 9.8% of total trade value.
Primary Market
Secondary Market
5Libya
Libya emerges as the fifth largest importing country, achieving a total trade value of $256.3K through 0 shipments. This represents a market share of 4.0% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: Libya demonstrates strong market positioning with an average shipment value of $256.3K, indicating premium pricing strategy compared to the market average of $57.0K.
Libya is a key market for Raltegravir imports, representing 4.0% of total trade value.
Primary Market
Secondary Market
*MAH DAROUYE HAKIM* (Iran): Engages in importing and distributing pharmaceuticals across Iran.
*NEW GPC INC* (Guyana): Distributes medical products within Guyana.
Distributors often place orders based on market demand, maintaining inventory levels to meet the needs of healthcare providers. Their purchasing behavior is influenced by market dynamics and demand forecasts.
3. Re-exporters: Entities that import products with the primary intention of exporting them to other markets.
*EMIRATES POST COMPANY* (United Arab Emirates): While primarily a postal service, it may engage in re-exporting pharmaceuticals due to the UAE's strategic location as a trade hub.
Re-exporters typically order large quantities to benefit from economies of scale, focusing on markets where they have established trade routes. Their order patterns are strategic, aiming to optimize logistics and market reach.
TransData Nexus Research · Government and regulatory sourcesMar 2026
4. Import Tariff/Duty for HS 30049099: Under the Central American Common Market (CACM), the average applied rate is approximately 2.4%.
Peru
1. Drug Regulatory Authority: General Directorate of Medicines, Supplies and Drugs (DIGEMID) under the Ministry of Health.
2. Import Registration Process for Raltegravir:
Submit a registration application to DIGEMID.
Provide detailed product information, including composition and manufacturing process.
Include certificates of Good Manufacturing Practices (GMP).
Submit clinical trial data if required.
Provide labeling and packaging information.
3. Estimated Timeline for Registration: Approximately 6-12 months.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products are generally subject to a 0% import duty in Peru.
Panama
1. Drug Regulatory Authority: National Directorate of Pharmacy and Drugs (DNFD) under the Ministry of Health.
2. Import Registration Process for Raltegravir:
Submit a registration application to DNFD.
Provide product dossier, including composition and manufacturing details.
Include GMP certificates.
Submit stability studies and clinical data if necessary.
Provide labeling and packaging samples.
3. Estimated Timeline for Registration: Approximately 6-9 months.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products typically have a 0% import duty in Panama.
Nepal
1. Drug Regulatory Authority: Department of Drug Administration (DDA) under the Ministry of Health and Population.
2. Import Registration Process for Raltegravir:
Submit an application to DDA.
Provide product details, including formulation and manufacturing process.
Include GMP certificates.
Submit clinical trial data if required.
Provide labeling and packaging information.
3. Estimated Timeline for Registration: Approximately 6-12 months.
4. Import Tariff/Duty for HS 30049099: Specific tariff information for HS 30049099 is not readily available; however, pharmaceutical products may be subject to import duties as per Nepal's tariff schedule.
Libya
1. Drug Regulatory Authority: Libyan Drug Control Center (LDCC) under the Ministry of Health.
2. Import Registration Process for Raltegravir:
Submit a registration application to LDCC.
Provide comprehensive product information, including composition and manufacturing details.
Include GMP certificates.
Submit clinical trial data if required.
Provide labeling and packaging samples.
3. Estimated Timeline for Registration: Approximately 6-12 months.
4. Import Tariff/Duty for HS 30049099: Specific tariff information for HS 30049099 is not readily available; however, pharmaceutical products may be subject to import duties as per Libya's tariff schedule.
TransData Nexus Research · Government and regulatory sourcesMar 2026
$282.73 per unit
*MAH DAROUYE HAKIM* (Iran): Engages in importing and distributing pharmaceuticals across Iran.
*NEW GPC INC* (Guyana): Distributes medical products within Guyana.
Distributors often place orders based on market demand, maintaining inventory levels to meet the needs of healthcare providers. Their purchasing behavior is influenced by market dynamics and demand forecasts.
3. Re-exporters: Entities that import products with the primary intention of exporting them to other markets.
*EMIRATES POST COMPANY* (United Arab Emirates): While primarily a postal service, it may engage in re-exporting pharmaceuticals due to the UAE's strategic location as a trade hub.
Re-exporters typically order large quantities to benefit from economies of scale, focusing on markets where they have established trade routes. Their order patterns are strategic, aiming to optimize logistics and market reach.
TransData Nexus Research · Government and regulatory sourcesMar 2026
4. Import Tariff/Duty for HS 30049099: Under the Central American Common Market (CACM), the average applied rate is approximately 2.4%.
Peru
1. Drug Regulatory Authority: General Directorate of Medicines, Supplies and Drugs (DIGEMID) under the Ministry of Health.
2. Import Registration Process for Raltegravir:
Submit a registration application to DIGEMID.
Provide detailed product information, including composition and manufacturing process.
Include certificates of Good Manufacturing Practices (GMP).
Submit clinical trial data if required.
Provide labeling and packaging information.
3. Estimated Timeline for Registration: Approximately 6-12 months.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products are generally subject to a 0% import duty in Peru.
Panama
1. Drug Regulatory Authority: National Directorate of Pharmacy and Drugs (DNFD) under the Ministry of Health.
2. Import Registration Process for Raltegravir:
Submit a registration application to DNFD.
Provide product dossier, including composition and manufacturing details.
Include GMP certificates.
Submit stability studies and clinical data if necessary.
Provide labeling and packaging samples.
3. Estimated Timeline for Registration: Approximately 6-9 months.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products typically have a 0% import duty in Panama.
Nepal
1. Drug Regulatory Authority: Department of Drug Administration (DDA) under the Ministry of Health and Population.
2. Import Registration Process for Raltegravir:
Submit an application to DDA.
Provide product details, including formulation and manufacturing process.
Include GMP certificates.
Submit clinical trial data if required.
Provide labeling and packaging information.
3. Estimated Timeline for Registration: Approximately 6-12 months.
4. Import Tariff/Duty for HS 30049099: Specific tariff information for HS 30049099 is not readily available; however, pharmaceutical products may be subject to import duties as per Nepal's tariff schedule.
Libya
1. Drug Regulatory Authority: Libyan Drug Control Center (LDCC) under the Ministry of Health.
2. Import Registration Process for Raltegravir:
Submit a registration application to LDCC.
Provide comprehensive product information, including composition and manufacturing details.
Include GMP certificates.
Submit clinical trial data if required.
Provide labeling and packaging samples.
3. Estimated Timeline for Registration: Approximately 6-12 months.
4. Import Tariff/Duty for HS 30049099: Specific tariff information for HS 30049099 is not readily available; however, pharmaceutical products may be subject to import duties as per Libya's tariff schedule.
TransData Nexus Research · Government and regulatory sourcesMar 2026
Analysis Methodology
1.Buyer Identification: 39 global importers of Raltegravir identified from consignee fields in DGFT shipping bill records.
2.Import Value Analysis: Total import value aggregated from 113 individual shipping bill records. Values are FOB in USD.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
4.Geographic Distribution: Buyer imports distributed across 27 destination countries with market share per buyer calculated from capped values.
